10 Hot Biotech Stocks Under $5 to Buy

8. Equillium, Inc. (NASDAQ:EQ)

Equillium, Inc. (NASDAQ:EQ), with a year-to-date gain of 89.68% and upside potential of 121.10%, secures a spot on our list of hot biotech stocks under $5 to buy.

Two analyst updates landed on the same day, both pointing to growing conviction around the company’s lead asset.

On May 28, 2026, Leerink upgraded Equillium, Inc. (NASDAQ:EQ) to “Outperform” from “Market Perform” and raised its price target to $6 from $1.

The firm cited growing clinical and mechanistic validation for aryl hydrocarbon receptor modulation in inflammatory bowel disease, pointing to an increasing body of supportive preclinical data for lead asset EQ504. Leerink sees meaningful potential for EQ504 in ulcerative colitis, noting growing support for the idea that aryl hydrocarbon receptor modulation can drive anti-inflammatory and barrier-restorative effects. The firm raised its probability of success for EQ504 in ulcerative colitis to 35% from 20% and forecast $1.5 billion in worldwide sales by 2035.

Raymond James also moved on May 28, 2026, lifting its price target on Equillium, Inc. (NASDAQ:EQ) to $7 from $6 while keeping a “Strong Buy” rating.

The firm described EQ504 as a selective AhR activator in development for the treatment of ulcerative colitis, with a Phase 1 SAD/MAD study expected in mid-2026. It sees potential upside if early data show strong target engagement, localized immune modulation, and a favorable safety profile without systemic immune suppression.

All covering analysts remain bullish on Equillium, Inc. (NASDAQ:EQ), with a median consensus price target of $6.50. Meanwhile, the stock was trading below $3 as of May 8, 2026.

Equillium, Inc. (NASDAQ:EQ) operates as a clinical-stage biotechnology company. It develops therapies for severe autoimmune and inflammatory disorders in the United States, focusing on conditions with significant unmet medical needs.